Abstract: Pharmaceutical compositions are provided according to aspects of the present disclosure which include a compound having chemical structural formula I: where R1 is selected from the group consisting of: an alkyl group, a heteroalkyl group, an aryl group, a heteroaryl group, an alkenyl group, a heteroalkenyl group, an alkynyl group, a heteroalkynyl group, a cycloalkyl group, a hetercycloalkyl group, an alkylcycloalkyl group, a heteroalkyl cycloalkyl group, an aralkyl group, a heteroaralkyl group, an alkoxy group, a polar group, an ester and a charged group; a pharmaceutically acceptable hydrolysable, or enzymatically cleavable, prodrug form thereof; and/or a pharmaceutically acceptable salt thereof; where R4? is H or an alkoxy group; where both R5 and R3? are OH, or where one or both OH groups is optionally modified as a pharmaceutically acceptable hydrolysable, or enzymatically cleavable, prodrug form thereof; and/or a deuterated form thereof; and/or a pharmaceutically acceptable salt thereof; and a pharma

Abstract: Pharmaceutical compositions are provided according to aspects of the present disclosure which include a compound having chemical structural formula I: where R1 is selected from the group consisting of: an alkyl group, a heteroalkyl group, an aryl group, a heteroaryl group, an alkenyl group, a heteroalkenyl group, an alkynyl group, a heteroalkynyl group, a cycloalkyl group, a hetercycloalkyl group, an alkylcycloalkyl group, a heteroalkyl cycloalkyl group, an aralkyl group, a heteroaralkyl group, an alkoxy group, a polar group, an ester and a charged group; a pharmaceutically acceptable hydrolysable, or enzymatically cleavable, prodrug form thereof; and/or a pharmaceutically acceptable salt thereof; where R4? is H or an alkoxy group; where both R5 and R3? are OH, or where one or both OH groups is optionally modified as a pharmaceutically acceptable hydrolysable, or enzymatically cleavable, prodrug form thereof; and/or a deuterated form thereof; and/or a pharmaceutically acceptable salt thereof; and a pharma

Abstract: There is a continuing need for methods and compositions relating to hormone-receptor-dependent cancers, including pharmaceutical compositions including one or more compounds having activity against steroid hormone-receptor-dependent cancer and methods of treatment of a steroid hormone-receptor-dependent cancer in a subject using said pharmaceutical compositions. ELK1 is a steroid hormone receptor tethering, protein that is implicated in hormone receptor dependent cancers. Compositions and methods according to aspects of the present invention inhibit the association of steroid hormone receptors with ELK1 providing activity against steroid hormone-receptor-dependent cancer.

Abstract: There is a continuing need for methods and compositions relating to hormone-receptor-dependent cancers, including pharmaceutical compositions including one or more compounds having activity against steroid hormone-receptor-dependent cancer and methods of treatment of a steroid hormone-receptor-dependent cancer in a subject using said pharmaceutical compositions. ELK1 Is a steroid hormone receptor tethering, protein that is implicated in hormone receptor dependent cancers. Compositions and methods according to aspects of the present invention inhibit the association of steroid hormone receptors with ELKL providing activity against steroid hormone-receptor-dependent cancer.

Abstract: Assay systems for identifying a compound characterized by anti-hormone receptor-dependent cancer activity are provided according to aspects of the present invention which include: I) a first recombinant cell including: 1) a reporter gene expression construct driven by a DNA binding domain recognition sequence; 2) an expression construct encoding a DNA binding domain and ELK1 lacking an ETS DNA binding domain; and 3) an expression construct encoding human androgen receptor (AR); and II) a second recombinant cell including: an androgen response element (ARE)-reporter gene expression construct including an ARE in operable linkage with a nucleic acid encoding a reporter; and an expression construct encoding AR, wherein in the presence of androgen, the AR enters the nucleus of the second recombinant cell and specifically binds to the ARE, thereby activating expression of the reporter gene in the second recombinant cell.

Abstract: A novel class of drugs for treating androgen receptor (AR) positive cancer including prostate cancer and breast cancer are described. The drugs include the chemical scaffolds of a high affinity androgen receptor ligand and a histone deacetylase inhibitor. Also described are compositions including the novel drugs and methods of treating AR positive cancer using the compositions.

Abstract: A method of diagnosing and treating a patient with or suspected of having at least one solid tumor that produces folate receptor type ? includes administering a biologically effective amount of at least one folate receptor ? inducer, specifically steroid receptor ligands, with or without aid from at least one histone deacetylase inhibitor, to increase the level of the folate receptor ? on the plasma membrane of cancer cells as well as the folate receptor ? in at least one type of body fluid, including, for example, serum, ascites and cerebrospinal fluid.

Abstract: The invention provides a method for treating leukemia in a patient. The method comprises administering to the patient a substance that increases expression of folate receptor &bgr; on leukemia cells in the patient, called a FR-&bgr; inducer, and administering a folate-conjugated therapeutic that targets the leukemia cells in the patient. The invention also comprises pharmaceutical compositions containing one or both of a FR-&bgr; inducer and a folate-conjugated therapeutic.